armata investors

Press Releases

AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday, November 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call:     U.S.   866-652-5200
      International   412-317-6060
      Passcode   10114360

Live Webcast:


AmpliPhi IR Website

      The webcast replay will be available approximately 2 hours after completion of the call and will be archived for 30 days.
Replay:     U.S.   877-344-7529
      International   412-317-0088
      Passcode   10114360
      The replay will be available for 48 hours starting approximately 2 hours after completion of the call.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit



At the Company: 
AmpliPhi Biosciences
Matthew Dansey
(858) 800-4869 
Investor Relations: 
Westwicke Partners
Robert H. Uhl
(858) 356-5932 
Russo Partners, LLC
David Schull or Maggie Beller
(212) 845-4271